key: cord-0756628-14egr2t8
authors: Laroye, Caroline; Gibot, Sébastien; Huselstein, Céline; Bensoussan, Danièle
title: Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID‐19
date: 2020-08-18
journal: Stem Cells Transl Med
DOI: 10.1002/sctm.20-0239
sha: 2fd9728ba89cfad7b91d62561692c7aa6d73c45a
doc_id: 756628
cord_uid: 14egr2t8

Sepsis is defined as life‐threatening organ dysfunction caused by a deregulated immune host response to infection. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has highlighted this multifactorial and complex syndrome. The absence of specific treatment neither against SARS‐CoV‐2 nor against acute respiratory distress syndrome (ARDS), the most serious stage of this infection, has emphasized the need to find alternative treatments. Several therapeutics are currently tested and among them, mesenchymal stromal cells. These cells, already used in preclinical models of ARDS, sepsis, and septic shock and also in few clinical trials appear well‐tolerated, promising, but many questions remain unanswered.

Mesenchymal stem/stromal cells (MSCs) were first described in the 1970s by Friedenstein's team in bone marrow (BM). 1 Such cells with a fibroblastic morphology were subsequently observed in many tissues like adipose tissue (AT), dental pulp, menstrual blood, or extraembryonic source such as Wharton's Jelly (WJ) or placenta, 2 these latter sources currently represent nearly 30% of clinical MSC products. 3 In 2006, the International Society for Cellular Therapy (ISCT) defined MSCs as (a) adherent to the cell culture plastic; (b) able to differentiate into osteocytes, chondrocytes, and adipocytes; and (c) with a phenotype that is positive for the CD73 CD90 CD105 mesenchymal markers and negative for the CD34 CD45 HLA-DR hematopoietic markers. 4 According to ISCT, if the expression "Mesenchymal stem cells" is mainly indicating a stem cell population with self-renewal and differentiation potential, the term "mesenchymal stromal cells" is used to design bulk unfractionated populations with secretory, immunomodulatory, and homing properties. 2, 5 As these latter properties are of great interest, capitalized in nearly 25% of current clinical trials, "MSCs" will from now on refer to MSCs. 6 Mesenchymal stem/stromal cells can modulate both innate and adaptive immunity by cell contacts, secretion of cytokines, chemokines, growth factors, and release of extracellular vesicles (EV). 7, 8 Regarding adaptive immunity, they can decrease the cytotoxicity of T lymphocytes, impair their proliferation but also their activation by inhibiting dendritic cell maturation and inducing regulatory T cells. In an inflammatory context, they inhibit the proliferation of B lymphocytes and their production of immunoglobulins. Regarding innate immunity, they notably decrease the production of reactive oxygen species by neutrophils and promote the M2 anti-inflammatory phenotype of macrophages. 9 MSCs influence the phenotype of immune cells and their cytokine secretions. However, this immunomodulation seems to depend on the inflammatory context. In 2013, Bernardo and Fibbe described the existence of two MSC phenotypes depending on the inflammatory context and the stimulation of their Toll Like Receptor (TLR). 10 MSCs can have immunosuppressive or immunostimulatory properties. In a cell anergy context, they could exhibit a pro-inflammatory phenotype, MSC1, making it possible to reduce apoptosis and promote T-cell survival. 11 On the other hand, in case of inflammation, they could adopt an immunosuppressive and anti-inflammatory phenotype, called MSC2. This change in phenotype depending on the inflammatory environment suggests new opportunities for therapeutic uses.

Surprisingly, these immunomodulatory cells whose behavior is modulated by the inflammatory context, appear little impacted by immune cells. As they lack MHC class II antigens and CD80/CD86 costimulatory molecules, they do not activate T cells but they induce T-cell anergy. As they weakly express MHC class I antigens, they are rarely targeted by NK cells. Thus, they can be used in an allogeneic setting without considering HLA compatibility thanks to their low immunogenicity. However, an instant blood mediated inflammatory reaction generated by systemically infused MSCs has been recently described and results from the triggering of the host innate immune cascade systems, such as complement and coagulation. The intensity of this reaction is dependent from the sources of MSCs and related to the expression of procoagulant tissue factor (TF). 3 Therefore, MSC therapy can be considered in the context of vital emergency pathologies such as sepsis or septic shock, provided special attention is paid to controlling the risk of their potential procoagulant activity. 12 

Since the emergence of the SARS-CoV-2, sepsis was put in the spotlight. Sepsis, a leading cause of admission to intensive care units, is a major socioeconomic burden all over the world. It is defined as lifethreatening organ dysfunction caused by a dysregulated immune host response to infection. 13, 14 Although sepsis induces a high mortality rate, there is currently no specific treatment for this complex syndrome, associating cytokine storm, excessive inflammation, but also immunosuppression and lymphocytopenia. [15] [16] [17] [18] Modulating inflammation while limiting the concomitant immunosuppression would certainly be the main therapeutic issue. Thus, MSCs, which pro-or antiinflammatory behavior is induced by the inflammatory environment, seem promising candidates to treat sepsis ( Figure 1 ). Currently, several preclinical studies have reported the protective action of MSCs in sepsis murine models and in its ultimate stage, septic shock. 19 MSCs improve survival, decrease organ failure, increase bacterial clearance, modulate cytokine production, and improve renal, pulmonary, liver, cardiac, and muscular functions. [20] [21] [22] [23] These benefic actions appear to be closely related to the strong immunomodulatory properties of MSCs. By reducing ambient inflammation and favoring antiinflammatory cytokines and mediators, they limit organ damages. [24] [25] [26] [27] These findings were found in small but also in large animal sepsis models. 28, 29 However, the design of the studies being very variable (severity of sepsis, time of treatment, MSC tissue source, dosage, etc.), some results may be contradictory. Although our work has shown that MSCs are effective in murine and swine septic shock models, improving survival, organ failure, and bacterial load, we did not observe any MSC impact on inflammatory secreted factors, unlike other studies. 28, 30 Similarly, in a porcine sepsis model, Horak et al did not find any impact of BM-MSCs on inflammation. 31 However, they did not observe either any beneficial effect of MSCs on organ failures, unlike us. Despite the report of contradictory results, a recent metaanalysis of 29 animal studies, including 1266 animals, demonstrated that MSC therapy was related to a significant lower mortality rate. 32 Moreover, cell tracing studies performed in rodents exhibited that MSCS distribute to a variety of tissues after IV infusion. They were found in the lung early after administration, then in the liver and the spleen. 33 However, the rationale for extrapolating data from small animals to humans remains weak. In addition to the classic questions about the correlation of animal models and human physiology, it should not be forgotten that the xenogenic context can strongly impact the results of the tested therapy, especially in the context of cell therapy. Animal-derived MSCs are not a solution either: the product evaluated in animals would not match with the drug used in humans. Finally, only clinical studies will make it possible to assess the promising effect of MSCs during sepsis. 34, 35 Less than 12 clinical studies related to MSC infusion for sepsis and its main complications, acute respiratory distress syndrome (ARDS) and septic shock, have already been published (Table 1) The occurrence of the SARS-CoV-2 infection, whose severe form is sepsis, may bring soon many answers on the clinical effect of MSCs.

Until now, only a few teams and clinical trials were interested in the use of these cells during sepsis. However, the pandemic, in the absence of any specific treatment, has led to intense research for innovative therapeutics and to many changes regarding MSCs. In a few weeks, up to 30 Time of infusion is also a concern. Many preclinical studies report MSC administration at an early stage of sepsis or even prophylactic context. However, this is not feasible in a clinical context. In addition, reluctance to infuse them at early disease stages is often observed.

MSC tissue source is also a concern. Although most clinical trials 

In conclusion, MSCs appear to be promising therapeutics in the indication of sepsis. Clinical trials in the COVID-19 will provide a lot of answers about the use of MSCs but may also be fatal to their use, in the absence of proof of efficacy. It will then be necessary to remember that COVID-19 is not the main etiology of sepsis, at the risk of putting aside their very promising use in bacterial sepsis due especially to their important antibacterial capacities.

The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells

Mesenchymal stem versus stromal cells

Mesenchymal Stromal Cell committee position statement on nomenclature

Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

Mesenchymal stem cells and immunomodulation: current status and future prospects

Peak MSC-are we there yet

Multipotent mesenchymal stromal cells and the innate immune system

Mesenchymal stem cells in health and disease

Enhancing mesenchymal stromal cell immunomodulation for treating conditions influenced by the immune system

Mesenchymal stromal cells: sensors and switchers of inflammation

Effect of mesenchymal stromal cells on T cells in a septic context: immunosuppression or immunostimulation?

Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application

The third international consensus definitions for sepsis and septic shock (Sepsis-3)

Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)

Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding

Sepsis and septic shock

Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy

COVID-19 -what should anaethesiologists and intensivists know about it? Anaesthesiol Intensive Ther

Mesenchymal stromal/stem cells: a new treatment for sepsis and septic shock?: MSCs in the treatment for sepsis and septic shock

Human umbilical cord mesenchymal stromal cells improve survival and bacterial clearance in neonatal sepsis in rats

The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143: poly(I:C) improves MSCs immune function

Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis

Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis

Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production

Treatment with human Whartons Jelly-derived mesenchymal stem cells attenuates sepsis-induced kidney injury, liver injury, and endothelial dysfunction

Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy

Administration of bone marrow stromal cells in sepsis attenuates sepsis-related coagulopathy

Clinical-grade mesenchymal stem cells derived from umbilical cord improve septic shock in pigs. Intensive

Bone marrow-derived mesenchymal stem cells in repair of the injured lung

Bone marrow vs Wharton's Jelly mesenchymal stem cells in experimental sepsis: a comparative study

Evaluation of mesenchymal stem cell therapy for sepsis: a randomized controlled porcine study

Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies

Umbilical cord mesenchymal stromal cell transplantations: a systemic analysis of clinical trials

Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19

Stem cell-based therapies for sepsis

Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

Cellular immunotherapy for septic shock (CISS): a phase I clinical trial

The results of the single center pilot randomized Russian clinical trial of mesenchymal stromal cells in severe neutropenic patients with septic shock (RUMCESS)

Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: a phase 1 clinical trial

Intravenous infusion of human adipose mesenchymal stem cells modifies the host response to lipopolysaccharide in humans: a randomized, single-blind, parallel group, placebo controlled trial: mesenchymal stem cells in human endotoxemia

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome

Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza a (H7N9) infection: a hint for COVID-19 treatment

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells

Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

MSC therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy

Trends in mesenchymal stem cell clinical trials 2004-2018: is efficacy optimal in a narrow dose range?

Mesenchymal stem/stromal cell production compliant with good manufacturing practice: comparison between bone marrow, the gold standard adult source, and Wharton's Jelly, an Extraembryonic source

Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice: MSC MV attenuates ALI in part through KGF

Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice

Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19

Preclinical translation of exosomes derived from mesenchymal stem/stromal cells

Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19